Biotechnology Healthcare - June 2008 - (Page BFAC2) SELF-STUDY CONTINUING EDUCATION ACTIVITY Biologic Therapy Management: The Need for Value-Based Health Benefits Models A statement of credit is offered to health care professionals who read pages 3 through 43 of this publication and submit the assessment and evaluation form on page 44. CME and CPE credit are offered. Estimated time to complete this activity is 3.75 hours. A statement of credit will be awarded upon successful completion of assessment questions (70 percent or better). If a score of 70 percent or better is not achieved, no credit will be awarded, and the registrant will be so notified. There is no fee for this activity. Target audience This program is targeted to medical directors, pharmacy directors, and other managed care health care professionals, as well as corporate medical directors and other employer health benefits decision makers. Overview In response to accelerating health care costs, payers and purchasers are shifting the cost burden to patients. This has created access barriers — particularly for biologic and targeted therapies, for which the cost burden can be substantial. The potential benefits associated with these therapies warrant examination in the context of health care coverage, financing, access, and administration. Medications developed through biotechnology research do not fit neatly within traditional benefitdesign structures. The cost of biotech injectable medications often requires significant out-ofpocket expenditures. Higher cost sharing under prescription drug and medical plans has a documented effect on patient access to care. The unintended consequences of limiting access and reimbursement for biologics could reverse wellmeaning attempts to control unnecessary health care resource utilization, and to reduce total health care expenditures and improve employer productivity. Educational objectives After reading this publication, participants will be able to: • Define the societal issues pertinent to patient access to appropriate health care treatment options. • Evaluate the role and value of biologics for chronically ill patients. • Advocate for policies surrounding access to, reimbursement for, and financing of biologics. Accreditation and designation This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Chatham Institute and BioCommunications LLC. The Chatham Institute is accredited by the ACCME to provide continuing medical education for physicians. The Chatham Institute designates this educational activity for a maximum of 3.75 AMA PRA Category 1 Credit(s). Physicians should claim credit commensurate with the extent of their participation in the activity. TM Planning committee members Christopher V. Goff, Esq., CEO and general counsel, Employers Health Purchasing Corp. of Ohio; Joel C. Hoffman, ASA, MAAA, FCA, managing principal, Reden & Anders; F. Randy Vogenberg, PhD, RPh, chief strategic officer, Employer-Based Pharmaceutical Strategies; Steven R. Peskin, MD, MBA, The Chatham Institute; and Michael D. Dalzell, editor of this monograph. Conflict-of-interest policy and disclosures of significant relationships It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. The Chatham Institute requires the disclosure of any significant financial interest or any other relationship a facility member may have with the manufacturer(s) of any commercial product(s) or device(s). Further, faculty members are required to disclosure discussion of any off-label uses in their presentation. Any faculty members not complying the disclosure policy are not permitted to participate in the educational activity. All program content has been peer reviewed for balance and any potential bias. The process to resolve conflicts of interest aims to ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical activities for the profession. The faculty of this program and the editorial staff of this monograph has disclosed the following: Christopher V. Goff, Joel Hoffman, F. Randy Vogenberg, Steven R. Peskin, Michael D. Dalzell, and Jack Alan McCain Jr., no conflicts of interest to report. Program sponsorship and support This activity is jointly sponsored by The Chatham Institute and BioCommunications LLC, and is supported by an educational donation provided by Amgen and Wyeth Pharmaceuticals. The Chatham Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 3.75 contact hours (0.375 CEU) of continuing education for pharmacists. ACPE Universal Program Number (UPN): 812-000-08-009-H01-P Release Date: March 15, 2008 Expiration Date: March 15, 2009 Medium: Journal supplement 2 BIOLOGIC THERAPY MANAGEMENT
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.